Neurodegeneration & Cognitive Resilience

Jati S, Kal S, Munoz-Mayorga D, Tang K, Sahoo D, Chen X, Mahata SK. (2026). Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition. Molecular Therapy. Epub ahead of print. doi: 10.1016/j.ymthe.2026.09.022. PMID: 42768750. VIEW PUBLICATION →

Jati S, Taheri S, Kal S, Sinha SC, Head BP, Mahata SK, Sahoo D. (2026). AI-guided discovery of a murine model of asymptomatic Alzheimer's disease. Acta Neuropathologica Communications. 14(1):110. PMCID: PMC13192062. VIEW PUBLICATION →

Jati S, Munoz-Mayorga D, Shahabi S, Tang K, Tao Y, Dickson DW, Litvan I, Ghosh G, Mahata SK, Chen X. (2025). Chromogranin A deficiency attenuates tauopathy by altering epinephrine-alpha-adrenergic receptor signaling in PS19 mice. Nature Communications. 16(1):4703. PMCID: PMC12092710. VIEW PUBLICATION →

Cardiovascular & Metabolic Therapeutics

Kal S, Chirasani VR, Biswas N, Mahata S, Jati S, Tang K, Pasqua T, Avolio E, Chitteti R, Chakraborty S, Bandyopadhyay G, Head BP, van den Bogaart G, Patel HH, Sahoo D, Senapati S, Mahata SK. (2026). Catestatin restores cardiac metabolic flexibility and enhances mitochondrial function. Communications Biology. 9(1):1110. PMCID: PMC13483899. VIEW PUBLICATION →

Muntjewerff EM, Epremidze D, Nezhyva M, Kal S, Rohm TV, Tang K, Singh K, Espes D, Jati S, Bootsma M, Mannaa AM, Ikebuchi H, Nilsson AM, Rajasekaran M, Andrén PE, Jansson ET, Mahata SK, Christoffersson G. (2025). Chromogranin A and catestatin regulate pancreatic islet homeostasis, endocrine function, and neurotransmitter signaling. Communications Biology. 8(1):1684. PMCID: PMC12658243. VIEW PUBLICATION →

Ying W, Tang K, Avolio E, Schilling JM, Pasqua T, Liu MA, Cheng H, Gao H, Zhang J, Mahata S, Ko MS, Bandyopadhyay G, Das S, Roth DM, Sahoo D, Webster NJG, Sheikh F, Ghosh G, Patel HH, Ghosh P, van den Bogaart G, Mahata SK. (2021). Immunosuppression of macrophages underlies the cardioprotective effects of CST (Catestatin). Hypertension. 77(5):1670–1682. PMCID: PMC8116433. VIEW PUBLICATION →

Dasgupta A, Bandyopadhyay GK, Ray I, Bandyopadhyay K, Chowdhury N, De RK, Mahata SK. (2020). Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: In vivo and in silico validation. Computational and Structural Biotechnology Journal. 18:464–481. PMCID: PMC7063178. VIEW PUBLICATION →

Ying W, Mahata S, Bandyopadhyay GK, Zhou Z, Wollam J, Vu J, Mayoral R, Chi NW, Webster NJG, Corti A, Mahata SK. (2018). Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity. Diabetes. 67(5):841–848. PMCID: PMC6463753. VIEW PUBLICATION →

Mahata SK, Kiranmayi M, Mahapatra NR. (2018). Catestatin: A master regulator of cardiovascular functions. Current Medicinal Chemistry. 25(11):1352–1374. PMID: 28443506. VIEW PUBLICATION →

Bandyopadhyay GK, Vu CU, Gentile S, Lee H, Biswas N, Chi NW, O'Connor DT, Mahata SK. (2012). Catestatin (chromogranin A(352–372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. Journal of Biological Chemistry. 287(27):23141–23151. PMCID: PMC3391131. VIEW PUBLICATION →

Oncology & Emerging Therapeutic Applications

Kal S, Jati S, Tang K, Webster NJG, Corti A, Mahata SK. (2026). Catestatin peptide impedes melanoma progression and drug resistance by reprogramming oncogenic signaling pathways. Oncogenesis. 15(1):39. PMCID: PMC13369845. VIEW PUBLICATION →

Gastrointestinal & Endocrine Biology

Muntjewerff EM, Tang K, Lutter L, Christoffersson G, Nicolasen MJT, Gao H, Katkar GD, Das S, Ter Beest M, Ying W, Ghosh P, El Aidy S, Oldenburg B, van den Bogaart G, Mahata SK. (2021). Chromogranin A regulates gut permeability via the antagonistic actions of its proteolytic peptides. Acta Physiologica. 232(2):e13655. PMCID: PMC8341099. VIEW PUBLICATION →

Foundational Discovery & CST Biology

Biswas N, Gayen J, Mahata M, Su Y, Mahata SK, O'Connor DT. (2012). Novel peptide isomer strategy for stable inhibition of catecholamine release: Application to hypertension. Hypertension. 60(6):1552–1559. PMCID: PMC3523723. VIEW PUBLICATION →

Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT. (2007). Catecholamine release-inhibitory peptide catestatin (chromogranin A(352–372)): Naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 115(17):2271–2281. PMID: 17438154. VIEW PUBLICATION →

Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. (2005). Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. Journal of Clinical Investigation. 115(7):1942–1952. PMCID: PMC1159140. VIEW PUBLICATION →

Mahata SK, Mahata M, Wakade AR, O'Connor DT. (2000). Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A (344–364)): Identification of amino acid residues crucial for activity. Molecular Endocrinology. 14(10):1525–1535. PMID: 11043569. VIEW PUBLICATION →

Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. (1997). Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. Journal of Clinical Investigation. 100(6):1623–1633. PMCID: PMC508344. VIEW PUBLICATION →